Oppenheimer Weighs in on UnitedHealth Group Inc’s Q2 2018 Earnings (UNH)

UnitedHealth Group Inc (NYSE:UNH) – Oppenheimer increased their Q2 2018 EPS estimates for UnitedHealth Group in a research note issued to investors on Tuesday. Oppenheimer analyst M. Wiederhorn now expects that the healthcare conglomerate will post earnings of $2.98 per share for the quarter, up from their previous forecast of $2.67. Oppenheimer has a “Outperform” rating and a $240.00 price objective on the stock.

Several other analysts also recently commented on UNH. Zacks Investment Research raised UnitedHealth Group from a “hold” rating to a “buy” rating and set a $219.00 price objective for the company in a research note on Thursday, September 21st. ValuEngine downgraded UnitedHealth Group from a “buy” rating to a “hold” rating in a research report on Thursday, October 5th. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $210.00 price target on shares of UnitedHealth Group in a research report on Tuesday, October 10th. Jefferies Group raised their target price on UnitedHealth Group from $215.00 to $225.00 and gave the stock a “buy” rating in a research report on Friday, October 13th. Finally, BMO Capital Markets started coverage on UnitedHealth Group in a research report on Monday, October 16th. They issued an “outperform” rating and a $250.00 target price for the company. Three analysts have rated the stock with a hold rating and twenty-five have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $241.30.

Shares of UnitedHealth Group (NYSE UNH) traded up $5.53 during trading hours on Thursday, reaching $238.43. The company’s stock had a trading volume of 5,124,800 shares, compared to its average volume of 3,398,473. The company has a market capitalization of $232,520.00, a price-to-earnings ratio of 22.26, a P/E/G ratio of 1.48 and a beta of 0.66. UnitedHealth Group has a 1-year low of $156.09 and a 1-year high of $238.96. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 0.52.

UnitedHealth Group (NYSE:UNH) last released its quarterly earnings results on Tuesday, January 16th. The healthcare conglomerate reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.50 by $0.09. UnitedHealth Group had a return on equity of 21.79% and a net margin of 5.25%. The firm had revenue of $52.06 billion for the quarter, compared to analyst estimates of $51.57 billion. During the same quarter in the previous year, the company posted $2.11 EPS. The business’s revenue was up 9.5% on a year-over-year basis.

Large investors have recently bought and sold shares of the business. BlackRock Inc. boosted its stake in UnitedHealth Group by 1.2% during the 2nd quarter. BlackRock Inc. now owns 69,430,416 shares of the healthcare conglomerate’s stock worth $12,873,786,000 after purchasing an additional 796,654 shares during the period. Vanguard Group Inc. increased its holdings in shares of UnitedHealth Group by 2.5% in the 2nd quarter. Vanguard Group Inc. now owns 64,578,618 shares of the healthcare conglomerate’s stock valued at $11,974,168,000 after purchasing an additional 1,588,516 shares in the last quarter. FMR LLC increased its holdings in UnitedHealth Group by 2.1% during the 2nd quarter. FMR LLC now owns 56,101,668 shares of the healthcare conglomerate’s stock valued at $10,402,371,000 after acquiring an additional 1,168,324 shares in the last quarter. Alliancebernstein L.P. increased its holdings in UnitedHealth Group by 2.3% during the 2nd quarter. Alliancebernstein L.P. now owns 7,906,936 shares of the healthcare conglomerate’s stock valued at $1,466,104,000 after acquiring an additional 174,290 shares in the last quarter. Finally, TIAA CREF Investment Management LLC grew its holdings in shares of UnitedHealth Group by 3.9% during the second quarter. TIAA CREF Investment Management LLC now owns 5,882,427 shares of the healthcare conglomerate’s stock worth $1,090,720,000 after buying an additional 223,524 shares in the last quarter. Institutional investors own 86.09% of the company’s stock.

In other news, CEO Larry C. Renfro sold 22,598 shares of the business’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $221.75, for a total transaction of $5,011,106.50. Following the completion of the sale, the chief executive officer now owns 195,314 shares of the company’s stock, valued at $43,310,879.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kenneth Irwin Shine sold 457 shares of the business’s stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $211.03, for a total transaction of $96,440.71. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 33,655 shares of company stock valued at $7,469,083. 0.89% of the stock is owned by insiders.

COPYRIGHT VIOLATION WARNING: “Oppenheimer Weighs in on UnitedHealth Group Inc’s Q2 2018 Earnings (UNH)” was first published by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://www.americanbankingnews.com/2018/01/18/oppenheimer-weighs-in-on-unitedhealth-group-incs-q2-2018-earnings-unh.html.

About UnitedHealth Group

UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.

Earnings History and Estimates for UnitedHealth Group (NYSE:UNH)

Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply